Kidney Stones

Kidney stones (nephrolithiasis) are hard mineral and salt deposits that form inside the kidneys when urine becomes supersaturated with stone-forming substances. Affecting roughly 1 in 11 Americans at some point in their lives, they are among the most painful urological conditions — producing sudden, severe flank pain that radiates to the groin, often accompanied by blood in the urine. Most stones pass spontaneously with adequate hydration and pain control, but larger stones require procedural intervention. Understanding stone type, underlying metabolic risk factors, and targeted dietary changes dramatically reduces the chance of recurrence.

Table of Contents

  1. Overview
  2. Types of Kidney Stones
  3. Causes and Risk Factors
  4. Symptoms
  5. Diagnosis
  6. Conventional Treatment
  7. Nutritional and Lifestyle Approaches
  8. Complications
  9. Prognosis
  10. Prevention
  11. Key Research Papers

Overview

Nephrolithiasis is the medical term for kidney stones — crystalline concretions that precipitate out of urine within the renal collecting system. When the concentration of certain solutes (calcium, oxalate, uric acid, phosphate, cystine) exceeds their solubility threshold, crystals nucleate and aggregate over weeks to months into stones that can range from the diameter of a grain of sand to several centimeters.

The lifetime prevalence in the United States has risen from roughly 3.8% in the late 1970s to approximately 8.8% by the early 2010s, a trend attributed to rising obesity rates, a more animal-protein-rich Western diet, and increasing ambient temperatures linked to greater dehydration. Men are affected roughly twice as often as women, though the gap has been narrowing. A first stone confers a 50% risk of recurrence within 10 years without preventive intervention.

Stones are classified by their chemical composition, which in turn guides treatment. Calcium-containing stones account for approximately 80% of all cases. The remainder comprise uric acid, struvite, and cystine stones. Accurate stone analysis after passage or surgical retrieval is essential — metabolic workup and dietary advice differ substantially by stone type.

Back to Table of Contents

Types of Kidney Stones

Calcium Oxalate Stones (~70% of all stones)

The most prevalent stone type, calcium oxalate monohydrate (whewellite) and dihydrate (weddellite) form when urinary calcium combines with oxalate. High urinary oxalate — from either excessive dietary intake or intestinal hyperabsorption — is the predominant driver. These stones are radiopaque and visible on plain abdominal X-ray. Counterintuitively, dietary calcium restriction worsens risk by leaving more free oxalate in the gut for absorption.

Calcium Phosphate Stones (~10% of calcium stones)

Calcium phosphate stones (hydroxyapatite or brushite) form in alkaline urine, unlike calcium oxalate stones which precipitate in acid or neutral urine. They are associated with renal tubular acidosis (RTA), primary hyperparathyroidism, and the use of carbonic anhydrase inhibitors such as topiramate or acetazolamide. Brushite stones are particularly prone to rapid regrowth and resist shock-wave lithotripsy.

Uric Acid Stones (~10% of stones)

Uric acid stones form exclusively in persistently acidic urine (pH < 5.5). Gout, metabolic syndrome, type 2 diabetes, chronic diarrhea, and a high purine diet (red meat, shellfish, organ meats, beer) all promote low urinary pH. These stones are radiolucent — invisible on plain X-ray but clearly seen on CT — making them a diagnostic pitfall. Urinary alkalinization with potassium citrate can dissolve existing uric acid stones without surgery, a therapeutic option unique to this stone type.

Struvite Stones (~5–15% of stones)

Struvite stones (magnesium ammonium phosphate) form exclusively in the setting of urinary tract infection (UTI) with urease-producing organisms — most commonly Proteus mirabilis, Klebsiella, and Pseudomonas. Urease splits urinary urea into ammonia, alkalinizing the urine and precipitating struvite. These stones can grow rapidly into large "staghorn" calculi that fill the entire renal collecting system. Women, people with recurrent UTIs, and those with urinary diversions or neurogenic bladders are at highest risk. Complete stone removal is required because residual fragments harbor bacteria and drive recurrence.

Cystine Stones (<1% of stones)

Cystine stones result from cystinuria, an autosomal recessive transport defect that impairs renal tubular reabsorption of the amino acids cystine, ornithine, lysine, and arginine (COLA). Because cystine is poorly soluble, it crystallizes in the urine to form hexagonal crystals visible on microscopy. Cystine stones tend to be recurrent, treatment-resistant, and begin in childhood or young adulthood. Management requires extreme hydration (urine output > 3 L/day), urinary alkalinization, and thiol-binding drugs (tiopronin, D-penicillamine).

Back to Table of Contents

Causes and Risk Factors

Dehydration and Low Urine Volume

Inadequate fluid intake is the single most important modifiable risk factor for all stone types. When daily urine output falls below 1 liter, solutes concentrate to levels that exceed saturation thresholds. Hot climates, strenuous exercise, high-sweat occupations, and inadequate water access are all risk amplifiers. Prospective studies show that achieving urine output of at least 2 to 2.5 liters per day halves the risk of first stone formation and recurrence.

Diet

Medical Conditions

Medications

Several drugs increase stone risk: calcium-containing antacids (hypercalciuria), loop diuretics (hypercalciuria), topiramate and acetazolamide (alkaline urine → calcium phosphate), high-dose vitamin C supplementation (converted to oxalate), indinavir (HIV protease inhibitor that crystallizes in urine), and laxative abuse (dehydration and hypokalemia).

Genetics

A family history of kidney stones doubles an individual's lifetime risk. Monogenic causes — cystinuria, primary hyperoxaluria (AGXT mutations), Dent disease, and adenine phosphoribosyltransferase deficiency — together account for roughly 10–15% of recurrent pediatric stone disease. Polygenic contributions to idiopathic hypercalciuria are also well established.

Back to Table of Contents

Symptoms

The clinical presentation of kidney stones depends on stone size, location within the urinary tract, and whether obstruction is present.

Renal Colic

The hallmark symptom is renal colic — sudden-onset, severe, cramping or wave-like pain in the flank that does not improve with position changes (distinguishing it from musculoskeletal back pain, which often improves with movement). Pain classically radiates from the costovertebral angle along the course of the ureter toward the ipsilateral groin, labia majora, or testicle as the stone migrates distally. Pain intensity fluctuates in waves as the ureter spasms around the stone. Patients often appear unable to find a comfortable position.

Hematuria

Blood in the urine — visible (gross hematuria) or microscopic — occurs in up to 90% of patients with an acute stone episode. The absence of hematuria does not exclude the diagnosis but should prompt consideration of alternative causes of flank pain.

Lower Urinary Tract Symptoms

As a stone approaches the ureterovesical junction, patients often experience urinary urgency, frequency, and a sensation of incomplete bladder emptying that mimics a urinary tract infection. Dysuria (painful urination) may also occur at this stage.

Nausea and Vomiting

Nausea accompanies severe renal colic in most cases, thought to result from shared autonomic innervation between the renal capsule and the celiac plexus. Vomiting can be severe enough to prevent oral hydration and analgesics, necessitating intravenous fluids and parenteral pain control.

Fever and Signs of Infection

The combination of urinary obstruction and infection constitutes a urological emergency. Fever, rigors, and flank tenderness with systemic signs of sepsis require urgent decompression (ureteral stent or percutaneous nephrostomy) along with broad-spectrum antibiotics. Delay risks urosepsis and septic shock.

Asymptomatic Stones

Many stones — particularly those residing in the renal calyces — are discovered incidentally on imaging performed for unrelated reasons (CT of the abdomen for other indications, renal ultrasound). These "silent" stones may remain asymptomatic for years or grow and eventually cause obstruction or pain.

Back to Table of Contents

Diagnosis

CT KUB — Gold Standard Imaging

Non-contrast computed tomography of the kidneys, ureters, and bladder (CT KUB) is the imaging gold standard, with sensitivity and specificity both exceeding 95%. It identifies virtually all stone types (including radiolucent uric acid stones), precisely measures stone size and density (Hounsfield units), localizes the stone within the urinary tract, and identifies hydronephrosis or perinephric stranding indicative of obstruction. Stone size and location on CT reliably predict spontaneous passage: stones ≤ 4 mm pass spontaneously in ~80% of cases; stones > 8 mm rarely pass without intervention.

Ultrasound

Renal ultrasound is preferred for initial evaluation in pregnant women, children, and patients requiring repeated imaging to reduce cumulative radiation exposure. It reliably detects hydronephrosis and larger stones (> 5 mm) within the kidney but has limited sensitivity for ureteral stones. Point-of-care ultrasound by emergency physicians has been validated as an appropriate first-line tool in many settings.

Plain Abdominal Radiograph (KUB film)

A plain X-ray can identify radiopaque calcium oxalate and calcium phosphate stones but misses uric acid and cystine stones. Its primary modern utility is monitoring the passage of a known radiopaque stone during watchful waiting without repeated CT radiation exposure.

Urinalysis and Urine Culture

Dipstick and microscopic urinalysis detects hematuria, pyuria, bacteriuria, and crystalluria. Characteristic hexagonal cystine crystals or coffin-lid struvite crystals may identify stone composition non-invasively. Urine pH provides important clues — persistently acidic urine (< 5.5) favors uric acid stones; persistently alkaline urine (> 7.0) in the context of infection suggests struvite. Urine culture is mandatory when fever or pyuria is present.

Stone Analysis

When a stone is passed or retrieved surgically, it should be sent for infrared spectroscopy or X-ray diffraction compositional analysis. Knowing the stone type is the single most important step toward targeted, evidence-based prevention.

Serum Metabolic Panel

Basic labs include serum calcium, phosphate, uric acid, creatinine, bicarbonate, and parathyroid hormone (if hypercalcemia is present). These screen for hyperparathyroidism, gout, renal tubular acidosis, and baseline renal function.

24-Hour Urine Collection

For recurrent stone formers, first-time stone formers with a strong family history, and all stone formers in children, a 24-hour urine collection on the patient's typical diet measures urinary volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, and creatinine. This metabolic workup identifies the specific urinary abnormalities driving stone formation — hypercalciuria, hyperoxaluria, hyperuricosuria, hypocitraturia, or low urine volume — and guides targeted pharmacotherapy. Two separate collections on different days improve the reliability of results.

Back to Table of Contents

Conventional Treatment

Watchful Waiting and Medical Expulsive Therapy

Stones ≤ 5–6 mm in a patient with adequate pain control, no signs of infection, preserved renal function, and a solitary kidney or bilateral obstruction can be managed conservatively. Medical expulsive therapy (MET) with the alpha-1 adrenergic blocker tamsulosin (0.4 mg daily) relaxes smooth muscle in the distal ureter, increasing spontaneous stone passage rates and reducing time to passage. A Cochrane meta-analysis found tamsulosin modestly but significantly increases passage rates for distal ureteral stones 5–10 mm. Nifedipine has also been used but has weaker evidence. Adequate analgesia (NSAIDs are preferred over opioids for renal colic), oral hydration, and close outpatient follow-up complete conservative management.

Extracorporeal Shock Wave Lithotripsy (ESWL)

ESWL uses focused acoustic shock waves delivered from outside the body to fragment stones into passable pieces. It is best suited for renal or proximal ureteral stones < 20 mm of moderate density (Hounsfield units < 900). It is non-invasive and performed under sedation, but requires a functioning ureter for fragment passage and may need repeated sessions. Dense calcium oxalate monohydrate and brushite stones are relatively resistant. ESWL is contraindicated in pregnancy, uncorrected bleeding diathesis, obstruction distal to the stone, and nearby arterial aneurysm.

Ureteroscopy (URS)

Flexible or semi-rigid ureteroscopy passes a thin scope through the urethra and bladder into the ureter or renal pelvis to visualize and treat stones with a holmium laser (laser lithotripsy) or basket extraction. URS is the preferred intervention for distal ureteral stones and for stones in patients with obesity, bleeding disorders, or anatomy unsuitable for ESWL. Stone-free rates for distal ureteral stones exceed 90%. Ureteral stenting after the procedure is common to prevent obstruction from post-procedure edema.

Percutaneous Nephrolithotomy (PCNL)

PCNL is the standard of care for large renal stones (> 20 mm), staghorn calculi, and stones that failed ESWL or URS. A nephroscope is inserted directly through the flank into the renal collecting system via a percutaneous tract, and stones are fragmented with an ultrasonic, pneumatic, or laser lithotripter and suctioned out. PCNL achieves single-session stone-free rates of 85–90% for large stones. Risks include bleeding, urine leak, and adjacent organ injury.

Uric Acid Stone Dissolution

Uric acid stones are uniquely amenable to medical dissolution. Oral potassium citrate or sodium bicarbonate alkalinizes the urine to pH 6.5–7.0, converting insoluble uric acid to soluble urate. Complete non-surgical dissolution is achievable over weeks to months with strict pH monitoring. Dietary purine restriction and allopurinol (for hyperuricosuria) complement alkalinization therapy.

Surgical Management of Struvite Stones

Complete removal of struvite stones is essential because stone fragments harbor the causative bacteria and perpetuate infection-driven growth. PCNL is the preferred method for large staghorn calculi. Post-operatively, culture-directed antibiotics treat residual infection. Acetohydroxamic acid (urease inhibitor) is sometimes used as adjunctive therapy to inhibit stone regrowth but carries significant side effects.

Pain Management

NSAIDs (ketorolac IV, indomethacin, diclofenac) are the analgesics of first choice for renal colic — they inhibit prostaglandin-mediated ureteral spasm and reduce renal pelvic pressure, treating both pain and contributing to stone passage. Opioids are reserved for severe pain unresponsive to NSAIDs or in patients with contraindications (GI bleeding, CKD). Antiemetics (ondansetron, metoclopramide) address nausea.

Back to Table of Contents

Nutritional and Lifestyle Approaches

High Fluid Intake

The most evidence-based dietary intervention for all stone types is achieving a 24-hour urine output of at least 2.5 liters. This typically requires drinking 3 or more liters of fluid daily, as insensible losses (respiration, sweat) account for roughly 0.5–1 liter. Water is the preferred fluid. Coffee and beer modestly reduce stone risk in observational studies. Grapefruit juice and cola beverages (high phosphoric acid and fructose) may increase risk. Patients should aim for pale yellow urine throughout the day as a practical proxy for adequate hydration.

Dietary Calcium

Paradoxically, adequate dietary calcium (1,000–1,200 mg/day from food) reduces calcium oxalate stone risk by binding oxalate in the intestinal lumen before absorption. Calcium supplements taken between meals — not with food — do not provide this binding effect and may increase risk. The landmark randomized controlled trial by Borghi et al. (NEJM 2002, PMID 11794148) showed a low-animal-protein, normal-calcium diet reduced recurrent calcium oxalate stones by 51% compared to the traditional low-calcium diet.

Oxalate Restriction

For calcium oxalate stone formers with documented hyperoxaluria, reducing high-oxalate foods is recommended. Foods highest in oxalate include spinach (750 mg/100g), rhubarb, beets, almonds, peanuts, chocolate, and black tea. Practical advice: limit serving sizes rather than eliminating all oxalate-containing foods, always pair oxalate-rich foods with calcium-rich foods (e.g., spinach salad with cheese), and avoid high-dose vitamin C supplementation (> 1,000 mg/day), which is metabolized to oxalate.

Reduce Sodium

A daily sodium intake below 2,300 mg (about 100 mEq) reduces urinary calcium excretion — the critical mediator of hypercalciuric stone disease. Reducing sodium by 100 mEq/day lowers urinary calcium by approximately 40 mg/day. Patients should minimize processed foods, cured meats, canned soups, and restaurant meals — the primary sources of dietary sodium in the American diet.

Moderate Animal Protein

A modest animal protein intake — approximately 0.8–1.0 g/kg/day — reduces urinary calcium and uric acid excretion while increasing urinary citrate. The DASH (Dietary Approaches to Stop Hypertension) diet — rich in fruits, vegetables, low-fat dairy, and whole grains, with moderate animal protein — was associated with a 40–45% lower risk of kidney stones in three large prospective cohorts (Taylor et al., JASN 2009, PMID 19221204).

Potassium Citrate

Citrate is a natural stone inhibitor — it complexes with calcium in urine, reducing calcium available to precipitate with oxalate or phosphate, and directly inhibits calcium crystal growth and aggregation. Low urinary citrate (hypocitraturia) is present in up to 60% of calcium stone formers. Potassium citrate (10–20 mEq twice or three times daily) raises urinary citrate and pH, reducing stone recurrence by 50–90% in trials. Lemon juice (½ cup real lemon juice diluted in 2 liters of water daily) provides roughly 20–40 mEq of citrate and may benefit patients unable to tolerate potassium citrate tablets, though clinical trial evidence is less rigorous.

Uric Acid Stone Dietary Modifications

Low-purine diet: restrict red meat, organ meats, shellfish, anchovies, sardines, and beer. Limit fructose (sugar-sweetened beverages, fruit juice). Avoid acute dehydration during exercise or illness. Urinary alkalinization — either pharmacologically with potassium citrate or with dietary emphasis on fruits and vegetables (which yield alkaline metabolic byproducts) — is central to management.

Magnesium

Magnesium binds oxalate in the intestine (similarly to calcium) and in urine, where it forms a soluble magnesium oxalate complex. Observational data support a weak association between higher dietary magnesium and lower stone risk, and some small RCTs show modest benefit from magnesium supplementation. However, evidence remains insufficient to recommend routine supplementation absent documented hypomagnesuria. Dietary magnesium from whole grains, legumes, and green vegetables is a safe first approach.

Back to Table of Contents

Complications

Urinary Obstruction and Hydronephrosis

A stone lodged in the ureter blocks the flow of urine from the kidney, causing upstream dilation of the renal pelvis and calyces (hydronephrosis). Mild, transient hydronephrosis resolves with stone passage. Prolonged obstruction — particularly complete obstruction lasting more than 2–4 weeks — causes progressive tubular atrophy and irreversible loss of nephron mass. The degree of renal functional recovery depends on the duration and completeness of obstruction.

Urinary Tract Infection and Urosepsis

Obstruction impairs the normal flushing mechanism that clears bacteria from the urinary tract. UTI in the presence of an obstructing stone constitutes an emergency — bacteria cannot be cleared from the obstructed segment by antibiotics alone, and rapid decompression (percutaneous nephrostomy or ureteral stent placement) is required alongside antibiotics. Urosepsis with obstructed pyelonephritis carries substantial mortality if decompression is delayed.

Acute Kidney Injury

Bilateral obstructing stones or a stone in a solitary functional kidney can cause acute obstructive nephropathy and acute kidney injury (AKI). Urgent urological decompression is required. Even unilateral obstruction can cause AKI in the setting of hemodynamic compromise, pre-existing CKD, or nephrotoxic drug exposure.

Chronic Kidney Disease

Patients with recurrent stones and repeated episodes of obstruction, infection, and surgical intervention face a heightened risk of chronic kidney disease (CKD). Population studies show that a history of kidney stones is associated with a 30–70% increased risk of CKD and a twofold higher risk of end-stage renal disease compared to stone-free individuals. Underlying metabolic disorders (primary hyperoxaluria, cystinuria, hyperparathyroidism) substantially accelerate renal functional decline.

Psychological Impact and Quality of Life

Recurrent renal colic — often striking without warning — generates significant anxiety and fear. Chronic pain, repeated emergency department visits, and functional limitations during stone episodes impair quality of life comparably to other chronic pain conditions. Validated patient-reported outcome measures (URQOL, WISQOL) capture this burden.

Back to Table of Contents

Prognosis

The vast majority of acute symptomatic kidney stones — particularly those ≤ 4–5 mm in the distal ureter — resolve without surgical intervention. Spontaneous passage rates reach 80% for stones ≤ 4 mm and fall to roughly 20% for stones > 8 mm. Stones that do require surgical intervention are managed with highly effective and minimally invasive procedures; mortality from acute urolithiasis is extremely low in developed health systems (< 0.1%).

Long-term prognosis depends largely on recurrence. Without preventive intervention, approximately 50% of patients experience a recurrence within 5–10 years and 75% within 20 years. Metabolic evaluation followed by targeted dietary and pharmacological prevention reduces this risk substantially. Patients who adhere to a high-fluid intake regimen alone reduce their 5-year recurrence rate by roughly 50%.

Patients with identifiable underlying metabolic disorders (primary hyperparathyroidism, distal RTA, primary hyperoxaluria, cystinuria) face more challenging courses and require specialist nephrology or urology follow-up with ongoing monitoring of stone burden, renal function, and metabolic parameters.

Back to Table of Contents

Prevention

Prevention is individualized to stone type and underlying metabolic abnormalities identified on 24-hour urine collection. General principles applicable to all stone formers:

Type-Specific Pharmacotherapy

Back to Table of Contents

Key Research Papers

  1. Scales CD Jr, Smith AC, Hanley JM, Saigal CS. Prevalence of kidney stones in the United States. European Urology. 2012;62(1):160–165. PMID: 22498635 — National cross-sectional analysis documenting an 8.8% lifetime prevalence, representing a marked increase from prior decades and establishing the epidemiological scope of nephrolithiasis in the US.
  2. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. New England Journal of Medicine. 1993;328(12):833–838. PMID: 8441427 — Landmark prospective cohort in 45,619 men establishing that high dietary calcium intake was inversely associated with kidney stone risk, overturning the recommendation to restrict calcium.
  3. Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. New England Journal of Medicine. 2002;346(2):77–84. PMID: 11794148 — Pivotal RCT demonstrating that a low-animal-protein, normal-calcium diet (not a low-calcium diet) reduced stone recurrence by 51% over 5 years, fundamentally reshaping dietary prevention guidelines.
  4. Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. Journal of the American Society of Nephrology. 2009;20(10):2253–2259. PMID: 19221204 — Pooled analysis of three large prospective cohorts showing a 40–45% lower stone risk in men and women with the highest adherence to the DASH dietary pattern.
  5. Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Annals of Internal Medicine. 2013;158(7):535–543. PMID: 23546565 — Comprehensive systematic review evaluating pharmacological prevention including thiazides, citrate, allopurinol, and acetohydroxamic acid, forming the basis of current ACP guidelines.
  6. Türk C, Petřík A, Sarica K, et al. EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. European Urology. 2016;69(3):468–474. PMID: 26318710 — The European Association of Urology's evidence-based guidance on imaging workup, medical expulsive therapy, and metabolic evaluation for stone disease.
  7. Hollingsworth JM, Rogers MA, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet. 2006;368(9542):1171–1179. PMID: 17011944 — Meta-analysis of 9 RCTs demonstrating that alpha-blockers (primarily tamsulosin) increase spontaneous stone passage rate by approximately 45% compared to placebo.
  8. Pearle MS, Calhoun EA, Curhan GC. Urologic Diseases in America Project: urolithiasis. Journal of Urology. 2005;173(3):848–857. PMID: 15711292 — Comprehensive economic and epidemiological analysis estimating more than $5 billion in annual US healthcare costs attributable to urolithiasis and documenting hospitalization trends.
  9. Frassetto L, Kohlstadt I. Treatment and prevention of kidney stones: an update. American Family Physician. 2011;84(11):1234–1242. PMID: 22150656 — Clinically oriented review covering dietary and pharmacological prevention strategies by stone type, well-suited for primary care application.
  10. Rule AD, Bergstralh EJ, Melton LJ 3rd, et al. Kidney stones and the risk for chronic kidney disease. Clinical Journal of the American Society of Nephrology. 2009;4(4):804–811. PMID: 19339427 — Population-based cohort study documenting a 1.7-fold increased risk of CKD and 1.6-fold increased risk of ESRD in kidney stone formers compared to matched controls.
  11. Daudon M, Frochot V, Bazin D, Jungers P. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs. 2018;78(2):163–201. PMID: 29374369 — Comprehensive review of medication-related nephrolithiasis, detailing mechanisms and management for indinavir, topiramate, vitamin C, and other implicated agents.
  12. Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Reviews in Urology. 2010;12(2–3):e86–e96. PMID: 20811556 — Global epidemiological review documenting rising prevalence worldwide and analyzing demographic, dietary, and environmental risk factors across continents.
  13. Featured Videos

PubMed Research Links

Back to Table of Contents

Connections

Back to Table of Contents